Wine-based antioxidant could shield against radiation exposure
An antioxidant contained in red table wine could one day prove effective as protection against radiation from a nuclear attack, according to a study by University of Pittsburgh researchers.
An antioxidant contained in red table wine could one day prove effective as protection against radiation from a nuclear attack, according to a study by University of Pittsburgh researchers.
The University of Pittsburgh's Center for Medical Countermeasures Against Radiation is dedicated to discovering and developing drugs that can be used as quick "antidotes" to mitigate or protect against the effects of radiation exposure in case of a large-scale radiological or nuclear emergency.
These new, small molecules with radioprotective capacity will be required for treatment in case of radiation spills or even as countermeasures against radiological terrorism, said lead investigator Dr. Joel Greenberger, chair of radiation oncology at Pitt's School of Medicine.
Greenberg and colleagues have been investigating the protective properties of resveratrol, a natural antioxidant commonly found in red wine and many plants. The investigators found that resveratrol, when altered with acetyl, proved to shield mouse cells to the effects of radiation. Their results were presented Sept. 23 at the 2008 American Society for Therapeutic Radiology and Oncology meeting in Boston.
"Small molecules that can be easily stored, transported, and administered are optimal for this, and so far acetylated resveratrol fits these requirements well," Greenberger said.
Greenberger's team is conducting further studies to determine if acetylated resveratrol can be used clinically as a radioprotective agent. His group had already made news in 2004 when they discovered the agent JP4-039, which can be delivered directly to mitochondria to resist radiation-induced cell death.
"Currently, there are no drugs on the market that protect against or counteract radiation exposure," Greenberg said. "Our goal is to develop treatments for the general population that are effective and nontoxic."
For more information from the Diagnostic Imaging archives:
Holiday travel can ring more than jingle bells
Dirty bombs: More fear than substance
ACR primer helps prepare for radiological terrorism
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
